Şükrü Oğuz ÖZDAMAR, Onak Nilüfer KANDEMİR, Nimet KARADAYI, Doğan Banu GÜN, Burak BAHADIR, Gamze YURDAKAN

CD10 expression in urothelial bladder carcinomas: Staining patterns and relationship with pathologic parameters

Amaç: CD10, çeşitli biyoaktif nöropeptitleri inaktive eden hücre yüzey metaloproteazıdır. CD10’un ürotelyal karsinomlarda prognostik belirleyici olarak kullanılabileceği öne sürülmektedir. Ancak ürotelyal tümörlerde CD10 ekspresyonunu araştıran az sayıda çalışma bulunmaktadır ve sonuçları farklılıklar göstermektedir. Bu çalışmada, ürotelyal mesane karsinomlarında CD10 ekspresyonu incelenmiş ve patolojik parametreler ile ilişkisi araştırılmıştır. Yöntem ve gereç: Toplam 50 ürotelyal mesane karsinomu arşiv materyallerinden seçilmiştir. Tüm olgularda histopatolojik bulgular tekrar gözden geçirilmiş ve WHO/ISUP 1998 sistemine göre derecelendirme uygulanmıştır. Patolojik evreleme için TNM sistemi kullanılmıştır. Her olgu için seçilen bir temsili doku bloğuna CD10 için immünhistokimyasal boyama işlemi gerçekleştirilmiştir. Bulgular: Elli olgununun 35 (% 70)’inde CD10 ekspresyonu belirlendi. Çalışmamızda düşük ve yüksek dereceli ürotelyal tümörler arasında CD10 immünreaktivitesinin yaygınlığı açısından istatistiksel olarak anlamlı farklılık belirlendi. CD10 ekspresyonu ile tümör boyutu, lenfovasküler invazyon varlığı ve patolojik evre arasında ilişki saptanmadı. Sonuç: Bulgularımız, yüksek dereceli ürotelyal karsinomlarda, düşük dereceli karsinomlara göre daha yüksek oranda CD10 ekspresyonu saptandığını göstermektedir. CD10 ürotelyal karsinomların progresyonunda ve diferansiyasyonunda rol oynayabilir.

Ürotelyal mesane karsinomlarında CD10 Ekspresyonu: Boyanma paterni ve patolojik parametreler ile ilişkisi

Aim: CD10 is a cell surface metalloprotease that inactivates various bioactive neuropeptides. CD10 has been suggested as a useful prognostic marker for urothelial carcinoma, but there are only a few studies of CD10 in urothelial tumors and they have shown varying results. The aims of this study were to investigate the expression of CD10 in urothelial bladder carcinomas and to clarify its association with pathologic parameters. Materials and methods: A total of 50 urothelial bladder carcinomas were selected from archival material. All cases were reevaluated histopathologically and graded according to the WHO/ISUP 1998 classification. The TNM system was used for their pathological staging. CD 10 immunohistochemical staining was performed on one representative tissue block for each case.Results: 35 of the 50 (70%) tumors showed positive CD10 immunostaining. We found a statistically significant difference in terms of CD10 extent between low grade and high grade tumors. No association was detected between CD10 expression and other pathologic parameters. No relationship was found between CD10 expression and tumor size, lymphovascular invasion, or pathological stage. Conclusion: According to our findings, high grade carcinomas showed a wider CD10 expression than that in low grade carcinomas. CD10 may play an important role in the progression and differentiation of bladder urothelial carcinomas.

PDF

___

1. Shipp MA, Stefano GB, D’Adamio L Switzer SN, Howard FD, Sinisterra J et al. Downregulation of enkephalin-mediated inflammatory responses by CD10/neutral endopeptidase 24.11. Nature 1990; 347: 394–396.
2. Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 1984; 82:1052–1070.
3. Arber DA, Weiss LM. CD10: a review. Appl Immunohistochem Mol Morphol 1997; 5: 125-140.
4. Ritz J, Pesando JM, Notis-McConarty J, Lazarus H, Schlossman F. A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature 1980; 283: 583–585.
5. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and bcl–6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000; 24: 846–852.
6. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Am J Clin Pathol 2000; 113: 374-382.
7. Metzgar RS, Borowitz MJ, Jones NH, Dowell BL. Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues. J Exp Med 1981; 154: 1249–1254.
8. Kaufmann O, Flath B, Späth-Schwalbe E, Possinger K, Dietel M. Immunohistochemical detection of CD10 with monoclonal antibody 56C6 on paraffin sections. Am J Clin Pathol 1999; 111: 117–122.
9. Mc Intosh GG, Lodge AJ, Watson P, Hall AG, Wood K, Anderson JJ et al. NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffin-embedded tissue. Am J Pathol 1999; 154: 77-82.
10. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D et al.. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 2000; 106: 1399–1407.
11. Dai J, Shen RQ, Sumitomo M, Goldberg JS, Geng Y, Navarro D et al. Tumor suppressive effects of neutral endopeptidase in androgen-independent prostate cancer. Clin Cancer Res 2001; 7: 1370-1377.
12. Ganju RK, Sunday ME, Tsarwhas DG, Card A, Shipp MA. CD10/ NEP in non-small cell lung carcinomas: relationship to cellular proliferation. J Clin Invest 1994; 94 (5): 1784-1791.
13. Ogawa H, Iwaya K, Izumi M, Kroda M, Serizawa H, Koyanagi Y et al. Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol 2002; 33: 806-811.
14. Iwaya K, Ogawa H, Izumi M, Kuroda M, Serizawa H, Koyanagi Y et al. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002; 440: 589-593.
15. Kanitakis J, Narvaez D, Claudy A. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res 2002; 12: 241–244.
16. Bircan S, Candir O, Kapucuoglu N. CD10 expression in urothelial bladder carcinomas: A pilot study. Urol Int 2006; 77: 107-113.
17. Murali R, Delprado W. CD10 ımmunohistochemical staining in urothelial neoplasms. Am J Clin Pathol 2005; 124: 371-379.
18. Koiso K, Akaza H, Ohtani M, Miyanaga N, Aoyagi K.A new tumor marker for bladder cancer. Int J Urol 1994; 1: 33-36.
19. Chu PG, Arber DA, Weiss LM, Chang KL. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 2001; 14(5): 465–71.
20. Kim MK, Kim S. Immunhistochemical profile of common epithelial neoplasms arising in the kidney. Appl Immunohistochem Mol Morphol 2002; 154: 77–82.
21. Simon R, Jones PA, Sidransky D, Hartmann A, Schmitz- Drager BC, Helpap B et al. Genetics and predictive factors of noninvasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein JI, et al, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:120–123. World Health Organization Classification of Tumours.
22. Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG. Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer 2000; 88: 1663–1670.
23. Lopez-Beltran A, Sauter G, Gasser T, Hartmann A, Schmitz- Drager BC, Helpap B et al. Infiltrating urothelial carcinoma. In: Eble JN, Sauter G, Epstein JI, et al, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004: 93–109. World Health Organization Classification of Tumours.
24. Lee R, Droller MJ. The natural history of bladder cancer: implications for therapy. Urol Clin N Am 2000; 27: 1-13.